Grau, Janina
Zöllner, Johann Philipp
Schubert-Bast, Susanne
Kurlemann, Gerhard
Hertzberg, Christoph
Wiemer-Kruel, Adelheid
Bast, Thomas
Bertsche, Astrid
Bettendorf, Ulrich
Fiedler, Barbara
Hahn, Andreas
Hartmann, Hans
Hornemann, Frauke
Immisch, Ilka
Jacobs, Julia
Kieslich, Matthias
Klein, Karl Martin
Klotz, Kerstin A.
Kluger, Gerhard
Knuf, Markus
Mayer, Thomas
Marquard, Klaus
Meyer, Sascha
Muhle, Hiltrud
Müller-Schlüter, Karen
Noda, Anna H.
Ruf, Susanne
Sauter, Matthias
Schlump, Jan-Ulrich
Syrbe, Steffen
Thiels, Charlotte
Trollmann, Regina
Wilken, Bernd
Willems, Laurent M.
Rosenow, Felix
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Funding for this research was provided by:
LOEWE CePTER
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 21 November 2020
Accepted: 29 May 2021
First Online: 21 June 2021
Declarations
:
: This study received ethics approval by the Goethe-University Frankfurt (reference 324/18) and all participants provided informed consent.
: Not applicable.
: JPZ reports speakers’ honoraria and travel grants from Eisai and Desitin Arzneimittel. SS-B reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UCB, and Zogenix. GK reports personal fees from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, UCB, Novartis, Takeda, and Zogenix. AW-K reports personal fees from Desitin Arzneimittel, GW Pharmaceuticals companies, Nutricia GmbH, Vitaflo, and UCB. TB reports personal fees from Eisai, Desitin Arzneimittel, GW Pharma, Novartis, Nutricia, Shire, Takeda, UCB Pharma and Zogenix. AB reports personal fees from Desitin Arzneimittel GmbH, Eisai GmbH, Shire GmbH, UCB Pharma GmbH, and ViroPharma GmbH. BF reports personal fees from Desitin Arzneimittel, Novartis and UCB. JJ reports personal fees from Eisai, GW Pharmaceuticals companies, Zogenix and has been supported by the German Research Foundation (DFG; JA 1725/4-1). KMK reports personal fees from UCB Pharma, Novartis Pharma AG, Eisai, and GW Pharmaceuticals, grants from the federal state Hessen through the LOEWE program and from the Canadian Institutes of Health Research. KAK reports personal fees from GW Pharmaceuticals companies and Zogenix and was supported by the Berta-Ottenstein-Program for Clinician Scientists from the Faculty of Medicine, University of Freiburg. TM reports personal fees and grants from Arvelle Therapeutics, Eisai, GW Pharmaceuticals companies, UCB, and Zogenix. HM reports personal fees from Desitin Arzneimittel, UCB, Novartis and Zogenix. SM reports grants from Novartis, UCB, Shire, Deutsche Forschungsgemeinschaft and Epilepsiestiftung Dr. Wolf. KMS reports personal fees from Nutricia, Desitin Arzneimittel, Shire, Medice, Novartis and UCB. MS reports personal fees from Novartis. RT reports personal fees from Eisai, Desitin, PTC Therap., Roche, Sanofi Genzyme. BW reports fees and compensation for travel expenses from Eisai, Takeda/Shire, Ipsen and PharmAllergan. FR reports personal fees from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Novartis, Medtronic, and UCB, and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the European Union. AS reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Marinus Pharma, UCB, and Zogenix. The other authors declare that they have no competing interests.